Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
The Food and Drug Administration has approved a new drug that claims to slow the progression of Alzheimer’s disease. The drug is the first approved for Alzheimer’s disease since 2003.
Healthcare AI has potential not only for neutralizing its inherent algorithmic bias but also for personalizing its outputs to help humans address health inequities.
Black-box AI should be barred from reading medical images in clinical settings because machine learning, like human thinking, tends to take diagnostic shortcuts.
Upon examining a skin lesion they suspected of being malignant, few dermatologists—only 8%—would hold back from performing a biopsy if an AI tool disagreed, classifying it as benign.
Explainable AI is almost as sharp as human experts when the cause is simple and straightforward, as with ingestion of a single common cleaning product.
JPMorgan Chase is forging a new path in the healthcare space following the downfall of Haven Healthcare, its recent joint venture with Amazon and Berkshire Hathaway.
